Sarah Nemec Biography and Net Worth

SVP, Finance and Principal Accounting Officer of Bolt Biotherapeutics

Sarah Nemec, Senior Vice President, Finance and Principal Accounting Officer, joined Bolt Biotherapeutics in 2020, bringing more than 20 years as a senior finance leader in the life science industry to the company. At Bolt, she is responsible for all aspects of the company’s financial planning, accounting, and reporting. Ms. Nemec played a key role in Bolt’s initial public offering and spearheaded all activities necessary to establish the company’s financial management infrastructure, key reporting systems and processes. Prior to joining Bolt, she served as the vice president, principal accounting executive for BioElectron Technology Corp., where she led accounting and cash management for the company through the sale and transition of its assets to PTC Therapeutics. Previously, Ms. Nemec served as the director, financial reporting for JDA Software (now Blue Yonder) and associate director, SEC reporting for Affymetrix (acquired by Thermo Fisher Scientific).

Ms. Nemec began her career as an auditor in the financial services and life science practice at Ernst & Young, LLP. Ms. Nemec is a certified public accountant and earned her bachelor’s and master’s degrees in accounting from Ohio University.

What is Sarah Nemec's net worth?: The estimated net worth of Sarah Nemec is at least $6.93 thousand as of June 5th, 2026. Ms. Nemec owns 1,924 shares of Bolt Biotherapeutics stock worth more than $6,926 as of October 8th. This net worth approximation does not reflect any other investments that Ms. Nemec may own. Learn More about Sarah Nemec's net worth.
How do I contact Sarah Nemec?: The corporate mailing address for Ms. Nemec and other Bolt Biotherapeutics executives is 900 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. Bolt Biotherapeutics can also be reached via phone at 650-665-9295 and via email at [email protected]. Learn More on Sarah Nemec's contact information.
Has Sarah Nemec been buying or selling shares of Bolt Biotherapeutics?: Sarah Nemec has not been actively trading shares of Bolt Biotherapeutics in the last ninety days. Most recently, Sarah Nemec sold 4,077 shares of the business's stock in a transaction on Friday, September 18th. The shares were sold at an average price of $3.24, for a transaction totalling $13,209.48. Following the completion of the sale, the vice president now directly owns 17,082 shares of the company's stock, valued at $55,345.68. Learn More on Sarah Nemec's trading history.
Who are Bolt Biotherapeutics' active insiders?: Bolt Biotherapeutics' insider roster includes Sarah Nemec (SVP, Finance and Principal Accounting Officer), William Quinn (CFO), and Grant Yonehiro (COO). Learn More on Bolt Biotherapeutics' active insiders.
Are insiders buying or selling shares of Bolt Biotherapeutics?: In the last twelve months, Bolt Biotherapeutics insiders bought shares 4 times. They purchased a total of 1,396 shares worth more than $5,598.98. In the last twelve months, insiders at the sold shares 9 times. They sold a total of 38,584 shares worth more than $128,361.21. The most recent insider tranaction occured on September, 18th when COO Grant Yonehiro sold 6,850 shares worth more than $22,194.00. Insiders at Bolt Biotherapeutics own 9.4% of the company. Learn More about insider trades at Bolt Biotherapeutics.
Information on this page was last updated on 9/18/2026.

Sarah Nemec Insider Trading History at Bolt Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/18/2026	Sell	4,077	$3.24	$13,209.48	17,082
9/17/2026	Sell	2,922	$3.32	$9,701.04	21,159
9/16/2026	Sell	843	$3.77	$3,178.11	24,081
6/5/2026	Buy	509	$3.88	$1,974.92	1,924
12/5/2025	Buy	125	$4.61	$576.25	1,415
6/6/2025	Buy	125	$5.49	$686.25	943
12/16/2024	Buy	125	$10.00	$1,250.00	831
6/6/2024	Buy	125	$12.80	$1,600.00	693

Sarah Nemec Buying and Selling Activity at Bolt Biotherapeutics

Bolt Biotherapeutics Company Overview

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Today's Range

Now: $3.68

$3.38

$3.79

50 Day Range

MA: $3.71

$3.20

$4.07

2 Week Range

Now: $3.68

$3.10

$7.20

Volume

54,001 shs

Average Volume

38,593 shs

Market Capitalization

$7.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Sarah Nemec Biography and Net Worth

What is Sarah Nemec's net worth?

How do I contact Sarah Nemec?

Has Sarah Nemec been buying or selling shares of Bolt Biotherapeutics?

Who are Bolt Biotherapeutics' active insiders?

Are insiders buying or selling shares of Bolt Biotherapeutics?